OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of “Moderate Buy” by Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $26.4444.

KIDS has been the topic of a number of research analyst reports. Truist Financial set a $22.00 price target on OrthoPediatrics in a report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Needham & Company LLC upped their target price on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th.

OrthoPediatrics Trading Down 2.3%

Shares of KIDS opened at $24.50 on Wednesday. The stock has a market capitalization of $639.70 million, a P/E ratio of -14.58 and a beta of 0.98. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $21.11 and a two-hundred day simple moving average of $18.53.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, research analysts anticipate that OrthoPediatrics will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC purchased a new stake in OrthoPediatrics in the second quarter worth about $5,161,000. Wasatch Advisors LP grew its holdings in shares of OrthoPediatrics by 56.6% during the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after acquiring an additional 186,357 shares during the period. Roubaix Capital LLC raised its position in shares of OrthoPediatrics by 23.8% in the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company’s stock worth $4,603,000 after acquiring an additional 55,724 shares in the last quarter. Granahan Investment Management LLC lifted its stake in shares of OrthoPediatrics by 35.1% in the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after purchasing an additional 232,760 shares during the period. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics during the second quarter valued at approximately $4,537,000. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.